allogene

allogene

[′a·lə‚jēn]
(geology)
A mineral or rock that has been moved to the site of deposition. Also known as allothigene; allothogene.
Mentioned in ?
References in periodicals archive ?
* With a rating of Buy, BTIG initiated coverage on Allogene Therapeutics Inc (NASDAQ: ALLO).
Building on our success with UCART19, an ALL target licensed to Servier and Allogene, this is the third wholly-owned Cellectis UCART product candidate to get clearance from the FDA to enroll patients in a Phase 1 clinical trial, after UCART123 in acute myeloid leukemia (AML) and UCART22 in B-cell acute lymphoblastic leukemia (B-ALL).
"The second quarter was an important one on many fronts, from advancing our pipeline with the clearance of our second investigational new drug application, to designing our state-of-the-art manufacturing facility and the continued onboarding of highly-skilled employees who are passionate about bringing allogeneic cell therapy to patients," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "Our teams are focused on advancing our allogeneic platform, which includes our first company-sponsored clinical trial with ALLO-501 for patients with relapsed/refractory non-Hodgkin lymphoma.
Vida's select investment portfolio consists of companies such as Allogene Therapeutics, AskBio, Homology Medicines, and Peloton Therapeutics, among others.
Bellco has a track record of co-founding and investing in companies, including Kite Pharma and Allogene Therapeutics.
Messemer currently serves on the board of directors of Allogene Therapeutics (NASDAQ: ALLO) and Carbon Inc.
Pour industrialiser leur usage, il faudrait aussi trouver un moyen d'utiliser des cellules de donneurs sains (cellules dites "allogeniques"), un obstacle sur lequel bon nombre de biotechs travaillent, dont la francaise Cellectis ou l'americaine Allogene Therapeutics.
Allogene is advancing its allogeneic CAR T portfolio acquired from Pfizer which included the rights to 16 preclinical CAR T assets licensed from Cellectis and Servier and U.S.
On April 3, 2018, Allogene and Pfizer announced that the companies had entered into a definitive asset contribution agreement for Pfizer's allogeneic CAR T portfolio.
(2) The French-Ivorian equivalents are etranger (a polysemous term for any non-local, regardless of origin), allogene (an external migrant originating from outside Cote d'Ivoire), and allochtone (an internal migrant from within Cote d'Ivoire).